During the period 2004-2017 we acted as lead external counsel to CSL Limited (ASX:CSL) and its subsidiary Seqirus Pty Ltd (aka CSL Biotherapies Pty Ltd) on contractual arrangements with the Commonwealth of Australia for the supply of seasonal influenza vaccine and other vaccines under the National Immunisation Plan as well as biosecurity commitments (including prototype pandemic vaccine development, pandemic preparedness commitments and supply of antivenoms and Q-Fever vaccine).
